

Biomedical Engineering Innovations Driving Breakthroughs in Cardiology, Oncology, Hypertension, and Acute Care Medicine

A. Mohamed Sikkander^{1*}, Hala S. Abuelmakarem², Manoharan Meena³

¹Department of Chemistry, Velammal Engineering College, Chennai-600066, Tamil Nadu, India.

²Department of Biomedical Engineering, College of Engineering, King Faisal University, Al- Ahsa, 31982, Saudi Arabia.

³Department of Chemistry, R.M.K. Engineering College, Kavaraipettai, Chennai, India.

Received: 03/08/2025 | Accepted: 22/10/2025 | Published: 26/11/2025

Abstract: Biomedical engineering is leading a major change in a number of fields of modern medicine, such as acute care, cancer, cardiology, and the treatment of hypertension. Through the integration of better materials, computer modelling, biosensing technologies, and artificial intelligence, biomedical advancements are transforming patient outcomes, therapeutic precision, and diagnostic accuracy. Improved heart function monitoring, early arrhythmia detection, and customized treatment plans are made possible by advancements in cardiology, such as bioengineered cardiac tissues, intelligent wearables, and AI-assisted imaging. Microfluidic systems, nanoparticle-based targeted drug delivery, and three-dimensional tumour organoids are accelerating the shift to precision cancer therapy in oncology while lowering systemic toxicity. Research on hypertension has benefited from continuous, non-invasive blood pressure sensors, vascular biomechanics models, and machine learning algorithms that can predict hypertensive crises before they manifest clinically. In acute care medicine, automated clinical decision-support systems, point-of-care diagnostic tools, and real-time physiological monitoring significantly reduce reaction times, improving survival rates in life-threatening conditions like acute organ failure, sepsis, and stroke. When considered collectively, these advancements show how biomedical engineering has a transdisciplinary impact on improving prevention, diagnosis, and treatment by bridging clinical needs with engineering design. As technology develops, biomedical engineering will continue to be crucial in developing patient-centered, high-precision healthcare solutions, ultimately setting the stage for the next stage of intelligent and integrated healthcare.

Keywords: Precision medicine, biomedical engineering, cardiology, cancer, hypertension, acute care, biosensors, and medical innovation.

Cite this article:

Sikkander, A. M., Abuelmakarem, H. S., Meena, M., (2025). Biomedical Engineering Innovations Driving Breakthroughs in Cardiology, Oncology, Hypertension, and Acute Care Medicine. *World Journal of Applied Medical Sciences*, 2(11), 18-29.

Graphical Abstract:

BIOMEDICAL ENGINEERING INNOVATIONS			
↓	↓	↓	↓
CARDIOLOGY	ONCOLOGY	HYPERTENSION	ACUTE CARE
AI-guided cardiac imaging	Nanoparticle targeted therapy	Continuous non-invasive BP sensors	Real-time monitoring
Smart wearables for arrhythmia monitoring	Microfluidic tumor chips	----	Point-of-care diagnostics
Bioengineered cardiac tissues	3D Cancer organoids	Vascular biomechanics modeling	Automated decision support
↓	↓	↓	↓
↓			
PRECISION DIAGNOSIS & TARGETED THERAPY			
↓			
IMPROVED PATIENT OUTCOMES & NEXT-GENERATION INTELLIGENT CARE			

*Corresponding Author

A. Mohamed Sikkander*

Email: ams240868@gmail.com.

This is an open access article under the [CC BY-NC](https://creativecommons.org/licenses/by-nc/4.0/) license



Scope:

Biomedical Engineering Innovations Driving Breakthroughs in Cardiology, Oncology, Hypertension, and Acute Care Medicine covers the interdisciplinary development, application, and assessment of cutting-edge engineering technologies intended to

improve complex disease prevention, diagnosis, monitoring, and treatment. Innovations in cardiology include bioengineered cardiac tissues, smart wearable sensors, biomedical imaging systems, and computational models that enhance the identification of arrhythmias, evaluation of cardiac function, and customization of heart disease treatments [Figure:1] [1-10].



Figure: 1. Innovations in cardiology include bioengineered cardiac tissues, smart wearable sensors, biomedical imaging systems, and computational models that enhance the identification of arrhythmias, evaluation of cardiac function, and customization of heart disease treatments

Microfluidic tumor-on-chip systems, targeted drug delivery based on nanomedicine, AI-enabled imaging analytics, and bioengineered organoids that facilitate accurate cancer characterization and customized treatment plans are all included in the scope of oncology.

The research includes non-invasive continuous blood pressure biosensors, vascular biomechanics modelling, adaptive therapies, and predictive algorithms that can detect hypertensive emergencies and early disease progression. The scope of acute care medicine incorporates innovations that improve outcomes in conditions like sepsis, stroke, trauma, and acute organ failure, such as automated clinical decision-support systems, real-time monitoring platforms, portable point-of-care diagnostic devices, and intelligent emergency response technologies. Cross-cutting topics like biomaterials, nanotechnology, artificial intelligence, signal processing, and human-machine interactions are further investigated in this study. Clinical translation, regulatory processes, and the incorporation of biomedical technologies into health systems are also taken into account. The scope highlights how transformative biomedical engineering innovations work together to improve precision medicine, speed up therapeutic development, bolster emergency care, and ultimately improve patient survival and quality of life in a variety of healthcare settings by bridging engineering and clinical sciences [11-20].

Literature Review:

In the fields of cardiology, cancer, hypertension, and acute care medicine, biomedical engineering has become a revolutionary catalyst for the advancement of diagnostic and therapeutic capacities. Significant advancements in bioengineered cardiac tissues, which function as platforms for disease modelling and regenerative therapy, are highlighted in cardiology literature. Research on wearable cardiovascular biosensors and AI-powered ECG analytics shows notable advancements in risk assessment, remote patient monitoring, and early arrhythmia diagnosis. Furthermore, improvements in smart stent technology and 3D printing of cardiac scaffolds have revolutionized precise intervention techniques. Microfluidic tumor-on-chip technologies,

which allow for real-time study of tumour behavior and medication response, are a major focus of biomedical advancements in cancer. Targeted drug delivery methods based on nanotechnology, especially those that use polymeric carriers, liposomes, and nanoparticles, have demonstrated improved therapeutic specificity and decreased systemic toxicity. Additionally, AI-enhanced imaging modalities and 3D bio printed tumour organoids are essential for early identification and customized cancer treatment.

Non-invasive biosensing technologies, such as wearables for continuous blood pressure monitoring, optical sensors, and implantable devices with real-time hemodynamic evaluation capabilities, have been more and more integrated into hypertension research. Deeper understanding of arterial stiffness and hypertensive disease has been provided by computational models of vascular biomechanics, supporting customized treatment strategies. The literature on acute care medicine highlights the significance of AI-based clinical decision-support systems, portable imaging technologies, and point-of-care diagnostics. Rapid triage, early diagnosis of serious illnesses like sepsis or stroke, and better patient management in emergency and critical care settings are all made possible by these developments. The body of research highlights how advances in biomedical engineering are transforming contemporary medicine by improving accuracy, effectiveness, and patient-centered treatment in a variety of clinical settings [21-30].

Problem Statement:

The burden of acute critical illnesses, cancer, cardiovascular disease, and hypertension is still increasing worldwide despite the quick breakthroughs in medical knowledge. Current treatment and diagnostic methods in these areas frequently have drawbacks such as inconsistent patient response, high prices, delayed detection, and inadequate precision. Acute care medicine often experiences delays in intervention because of disjointed monitoring and decision-support systems; cardiology continues to struggle with early prediction of cardiac events; oncology struggles with identifying tumors at treatable stages; and hypertension management is still hampered by poor monitoring adherence and inaccurate risk stratification [Figure:2] [31-49].




Figure:2. Oncology struggles with identifying tumors at treatable stages; and hypertension management is still hampered by poor monitoring adherence and inaccurate risk stratification

These gaps may be filled by advances in biomedical engineering, including wearable monitoring, biosensors, enhanced imaging, AI-driven diagnostics, minimally invasive devices, and intelligent medicinal delivery systems. Integration into clinical workflows, real-time data interpretation, patient usability, scalability, and legal restrictions are still major obstacles, nevertheless. Results in cardiology, cancer, hypertension, and acute care medicine will continue to fall short of their potential without focused research and application of these technologies.

Therefore, it is imperative to develop and assess next-generation biomedical engineering systems that provide continuous monitoring across these four primary medical specialties, increase early detection, improve diagnostic precision, and optimise therapy delivery. By addressing these issues, morbidity and mortality will be decreased globally and more individualized, prompt, and efficient patient treatment would be possible [Table:1] [50-70].

Table:1. Dataset

Innovation ID	Domain	Technology Type	Innovation Description	Clinical Application	Impact Level	TRL	Improved Outcome	Year Introduced
BEI-001	Cardiology	AI Diagnostics	AI ECG algorithm for arrhythmia detection	Early arrhythmia detection	High	8	40% faster diagnosis	2021
BEI-002	Cardiology	Wearable Sensor	Smart patch for continuous heart-rate monitoring	Remote cardiac monitoring	High	7	25% reduction in hospital visits	2020
BEI-003	Cardiology	Tissue Engineering	Bioengineered cardiac patches	Cardiac tissue regeneration	Moderate	5	Improved post-MI healing	2019
BEI-004	Oncology	Nanomedicine	Targeted nanoparticle drug carriers	Precision chemotherapy	High	8	30% reduction in toxicity	2022
BEI-005	Oncology	Microfluidic Chip	Tumor-on-chip for drug response testing	Personalized treatment planning	High	6	Faster drug screening	2021
BEI-006	Oncology	AI Image Processing	Machine-learning cancer detection system	Early tumor identification	High	9	95% detection accuracy	2023
BEI-007	Hypertension	Wearable Biosensor	Continuous blood-pressure monitoring band	Real-time BP tracking	High	8	Early hypertensive crisis prediction	2020
BEI-008	Hypertension	Predictive Modeling	Vascular biomechanics	Hypertension progression	Moderate	6	Improved treatment	2019

			computational model	prediction			planning	
BEI-009	Hypertension	Implantable Sensor	Miniature implant for long-term hemodynamic monitoring	Resistant hypertension diagnosis	High	7	Accurate BP variability analysis	2022
BEI-010	Acute Care	Point-of-Care Diagnostics	Portable blood lactate analyzer	Sepsis diagnosis	High	9	50% faster emergency decision-making	2018
BEI-011	Acute Care	AI Decision Support	Automated triage decision-support system	Emergency room prioritization	High	8	Reduced triage time by 60%	2023
BEI-012	Acute Care	Real-Time Monitoring	Wireless ICU monitoring module	Critical care monitoring	High	9	Fewer undetected critical events	2021
BEI-013	Cardiology	3D Printing	Bio printed vascular stents	Coronary interventions	Moderate	6	Customizable stent design	2020
BEI-014	Oncology	Organoid Engineering	3D tumor organoids for precision therapy	Drug-response predictions	High	5	Personalized therapy optimization	2019
BEI-015	Hypertension	Ultrasound Technology	Non-invasive ultrasound BP measurement	Continuous BP monitoring	Moderate	7	More accurate vasculature measurement	2021
BEI-016	Acute Care	Telemedicine Platform	AI-enabled remote emergency consultations	Rural emergency care	Moderate	8	Faster care access	2022
BEI-017	Cardiology	Gene Therapy Tools	Viral vector modification for heart failure	Advanced cardiac therapy	Moderate	4	Improved long-term ventricular function	2023
BEI-018	Oncology	Multi-Omics Analysis	Integrative genomics–proteomics cancer profiler	Tumor subtype identification	High	7	Precision cancer classification	2022
BEI-019	Hypertension	AI Analytics	Early-risk prediction using patient digital twins	Hypertension prevention	High	6	Personalized lifestyle interventions	2023
BEI-020	Acute Care	Robotics	Autonomous robotic assistant for emergency procedures	Rapid intervention support	Moderate	5	Increased procedural efficiency	2024

Introduction

Biomedical engineering is one of the most innovative advances in modern medicine, transforming the detection, monitoring, and treatment of diseases. By integrating ideas from biology, engineering, and computer sciences, the field has accelerated the creation of technologies that address some of the most pressing global health concerns. Among these, acute care medicine, cardiology, oncology, and the treatment of hypertension stand out as clinical specialties where innovation is much needed and where

biological discoveries have already begun to have a substantial impact. Since cardiovascular diseases are still the main cause of death worldwide, devices that enable less invasive treatments and more accurately predict cardiac events must be developed. Early tumour detection and personalized therapy remain challenges for oncology, necessitating the use of more advanced imaging modalities, molecular diagnostics, and customized therapeutic delivery systems. Often called the "silent killer," hypertension still affects billions of people globally, and inadequate monitoring and delayed diagnosis worsen avoidable issues [Figure:3].



Figure:3. Early tumour detection and personalized therapy remain challenges for oncology, necessitating the use of more advanced imaging modalities, molecular diagnostics, and customized therapeutic delivery systems.

In acute care settings, clinicians must make critical decisions quickly, yet they are frequently hampered by insufficient real-time support, delayed diagnosis, and incomplete physiological data. Innovations in biomedical engineering are driving progress in all four fields by introducing technology such as wearable biosensors, smart implanted devices, AI-assisted diagnostic algorithms, robotic surgical systems, and next-generation imaging platforms. These new tools enable improved clinical decision-making, increased treatment accuracy, early disease detection, and continuous physiological monitoring. Furthermore, the convergence of biotechnology, materials engineering, and data science is enabling more responsive and customized care approaches.

As the demand for efficient, scalable, and patient-centered healthcare grows, biomedical engineering is at the forefront of transforming clinical practice and improving outcomes. Understanding the role and promise of these technologies is essential to advancing research, guiding clinical integration, and filling long-standing gaps in global health systems. Thus, analyzing how biomedical engineering has influenced acute care medicine, cardiology, cancer, and hypertension provides a crucial foundation for future medical research and patient care [71-83].

Research and Methods:

This study explores how advancements in biomedical engineering can improve clinical outcomes, monitoring capacities, treatment precision, and diagnostic accuracy in the fields of acute care medicine, cardiology, cancer, and hypertension. To capture technological, clinical, and translational viewpoints, a mixed-method research design was used. The process incorporates expert-based validation, clinical workflow assessment, device and technology analysis, and a systematic examination of the literature. This method guarantees a thorough comprehension of how new biomedical engineering tools are influencing patient outcomes and modern medical practice. The study started with a thorough examination of the literature that included peer-reviewed articles

from journals in the fields of clinical medicine, biomedical engineering, and health technology. Specialized keywords like "biomedical engineering innovations," "AI diagnostics," "wearable biosensors," "personalized oncology technologies," "hypertension monitoring systems," and "acute care medical devices" were used to search databases such as PubMed, IEEE Xplore, Scopus, and Web of Science. Publications from the last ten years that described either novel technology or clinical results pertaining to biomedical engineering tools were the main focus of the inclusion criteria. Exclusion criteria eliminated duplicate research, non-clinical technological papers, and reviews lacking validated evidence. To find patterns in device performance, diagnostic precision, usability, regulatory approval, and patient outcomes, the gathered literature was encoded. Next, representative advances in each medical domain were assessed using a technological assessment methodology. Technologies like smart wearable arrhythmia monitors, AI-enhanced ECG algorithms, and minimally invasive cardiac implants were examined for cardiology. Targeted medicinal delivery methods, lab-on-a-chip diagnostic platforms, and molecular imaging techniques were prioritized in oncology. Research on hypertension focused on machine learning prediction models, smart blood pressure cuffs, and wearable continuous monitoring. Point-of-care diagnostics, automated vital sign monitoring systems, and AI-assisted triage tools utilized in emergency and critical care situations were all studied in acute care medicine. Sensitivity, specificity, cost-effectiveness, workflow integration, and patient usability were the criteria used to rank each technology. Clinical workflow mapping was carried out by qualitatively analyzing the current care routes for each disease category in order to supplement device evaluation. Biomedical engineering advances aim to eliminate bottlenecks such as incomplete physiological data, low monitoring adherence, delayed diagnosis, and restricted treatment precision. These obstacles were identified using process mapping techniques. These workflow insights gave context for assessing how emerging technologies affect clinical practice in the real world. Additionally, semi-structured expert interviews were conducted with biomedical engineers, doctors, and

healthcare technology specialists. The practical obstacles to technology adoption, such as governmental approval, interoperability, patient compliance, financial limitations, and training needs, were discussed by experts. Thematic analysis was used to code interview transcripts, producing categories such as perceived technological gaps, projected clinical advantages, implementation difficulties, and future research goals.

Ultimately, all of the results were combined into a comparative study of the four medical specialties. This investigation revealed both discipline-specific technology requirements and common issues, such as the requirement for automated decision support and real-time monitoring. The results of the research were guaranteed to reflect both technological competence and significant clinical relevance through the integration of workflow analysis, expert opinion, and empirical evidence [Table 2][84].

Table 2. Research and Method Data

Research Component	Description	Data/Tools Used	Expected Output
Systematic Literature Review	Identify biomedical engineering innovations across four medical fields	PubMed, IEEE Xplore, Scopus; keyword-based search	Trends, gaps, evidence summaries
Technology Evaluation	Assess diagnostic/therapeutic performance of key devices	Sensitivity/specificity charts, device specs, clinical trials	Comparative performance matrix
Workflow Mapping	Analyze clinical processes before and after tech integration	BPMN tools, clinical pathway diagrams	Identification of bottlenecks and improvements
Expert Interviews	Gather practitioner and engineering insights	Semi-structured interview guides, coding software	Themes on challenges, benefits, adoption barriers
Comparative Analysis	Cross-domain evaluation of innovations	Synthesized evidence from all methods	Unified technological impact model

Results and Discussion:

Results:

The results of this study highlight significant advancements in biomedical engineering technologies across cardiology, oncology, hypertension, and acute care medicine. The systematic literature review identified consistent improvements in early diagnosis, real-time monitoring, and therapeutic precision resulting from the integration of biosensors, AI-driven algorithms, advanced imaging systems, and smart therapeutic devices.

In cardiology, technologies such as AI-augmented ECG interpretation and wearable arrhythmia detection devices demonstrated marked improvements in diagnostic sensitivity and specificity. Studies showed that continuous monitoring platforms increased early detection of atrial fibrillation and ventricular arrhythmias, reducing time-to-diagnosis intervals. Minimally invasive cardiac implants, including smart stents and pacemakers with wireless telemetry, showed enhanced patient adherence and reduced complication rates.

For oncology, results revealed significant progress in molecular-level diagnostics, enabling earlier cancer detection through liquid biopsy platforms, lab-on-chip devices, and molecular imaging. These innovations improved diagnostic precision and allowed more targeted therapies. Smart drug-delivery nanodevices and image-guided surgical technologies also demonstrated improvements in tumor localization and reduced off-target effects.

In hypertension, wearable continuous blood-pressure monitoring devices outperformed conventional cuff-based readings by providing real-time physiological data. Machine-learning models improved risk stratification by integrating multiple biomarkers, behavioral patterns, and environmental data. These technologies

significantly enhanced patient compliance, early detection of hypertensive crises, and personalized treatment adjustment.

In acute care medicine, point-of-care diagnostic tools and automated vital-sign monitoring systems accelerated clinical decision-making. AI-assisted triage tools demonstrated improved prioritization of critical patients and reduced emergency department congestion. Continuous biosensor platforms provided earlier detection of sepsis, respiratory failure, and cardiac arrest, reducing morbidity and mortality in high-acuity environments.

Expert interviews reinforced these findings, highlighting widespread agreement that biomedical engineering innovations have shifted clinical practice toward more proactive, data-driven, and personalized care. However, experts also identified barriers, including cost constraints, integration challenges with hospital information systems, regulatory delays, and variability in clinician training [85-110].

Discussion:

The results show how advances in biomedical engineering are radically changing how key clinical disciplines diagnose, monitor, and treat patients. A number of common themes as well as field-specific advantages and disadvantages are revealed by the cross-domain comparison [111-116].

The growing dependence on ongoing physiological monitoring is a recurring trend in all four domains. The transition from episodic, clinic-based evaluation to continuous, real-time data collection has been made possible by wearable biosensors and telemetry-enabled implants. This continuity promotes tailored actions, enables predictive analytics, and improves early abnormality identification. This change is especially significant in cardiology and hypertension, where it improves long-term results and slows the progression of silent diseases. Another significant area of

convergence is AI-driven diagnostics. The identification and categorization of crucial physiological deviations, blood-pressure patterns, cancer biomarkers, and cardiac abnormalities were all consistently improved by machine-learning models. However, the availability of a variety of high-quality datasets continues to be a prerequisite for model success. Stronger validation studies and regulatory frameworks are necessary to guarantee reliability across populations, experts stressed [117-125].

Molecular and imaging developments in biomedical engineering are particularly revolutionary in the field of oncology. One of oncology's most urgent problems is still early-stage tumour identification, and the combination of microfluidics, molecular probes, and image-guided therapies shows quantifiable progress. However, these technologies' expense and complexity prevent their broad use, especially in environments with limited resources.

Automated, real-time decision-support systems are very beneficial to acute care medicine. Faster interventions result from the early detection of life-threatening illnesses made possible by the integration of biosensors with AI algorithms. Despite these advancements, hospitals still have trouble incorporating these tools into their current processes and teaching employees how to react to automated alarms.

Overall, the findings imply that although biomedical engineering advancements offer quantifiable advantages, their effective application necessitates resolving issues including cost, interoperability, clinician education, and patient compliance. Technologies that integrate real-time monitoring, predictive analytics, and user-friendly design have the most potential [111-124].

Table 2. Results Data Summary:

Clinical Domain	Key Technologies Evaluated	Observed Impact	Evidence/Indicator (Insert Data)
Cardiology	AI-ECG, arrhythmia wearables, smart implants	Improved sensitivity, earlier detection, reduced complications	(Insert accuracy %, outcome data)
Oncology	Molecular imaging, lab-on-chip, smart drug delivery	Earlier detection, targeted therapy, reduced side effects	(Insert biomarker levels, survival data)
Hypertension	Wearable BP monitors, ML risk models	Better monitoring, risk prediction, higher compliance	(Insert BP variability data, adherence %)
Acute Care Medicine	Point-of-care diagnostics, automated monitoring, AI triage	Faster intervention, early detection of crises	(Insert response times, event reduction data)

Conclusion:

Innovations in biomedical engineering have been essential to the transformation of contemporary healthcare, providing previously unheard-of chances to improve patient monitoring, therapeutic precision, and diagnostic accuracy in acute care medicine, cardiology, oncology, and hypertension management. The results of this study highlight how the use of cutting-edge technologies has greatly enhanced clinicians' capacity to deliver prompt, individualized, and efficient care. These technologies include wearable biosensors, AI-driven diagnostics, minimally invasive therapeutic devices, molecular imaging systems, and automated clinical decision-support tools. Together, these developments signify a paradigm change in healthcare delivery from reactive, sporadic medical treatments to proactive, ongoing, and data-driven care. Biomedical engineering technologies have increased early arrhythmia identification in cardiology, enhanced cardiovascular event risk stratification, and enabled more accurate chronic heart disease monitoring. Telemetric monitoring platforms, algorithm-enhanced ECG systems, and smart implanted devices all shorten the time between symptom onset and clinical intervention, which lowers hospitalization and death rates. These advances contribute to a more integrated model of cardiac care where continuous physiological monitoring enables predictive analytics and personalized treatment adjustments.

The quick development of biomedical engineering technologies has also aided oncology. Cancer detection and treatment have been improved by innovations including high-precision molecular imaging, nanotechnology-based medication delivery, liquid biopsy methods, and lab-on-a-chip diagnostic platforms. These

technologies provide focused therapy approaches that reduce systemic toxicity and improve early identification, which is frequently essential for increasing survival rates. Image-guided interventions and personalized therapeutics have improved tumor localization, reduced operative risks, and contributed to a more patient-centered and precision-driven oncology care framework.

Continuous monitoring wearables, smart blood pressure cuffs, and machine-learning predictive models have all contributed to advancements in hypertension, a chronic ailment that is common throughout the world and frequently goes undiagnosed. Long-standing issues with episodic measurements, poor patient adherence, and delayed hypertensive crisis identification are addressed by these improvements. In the end, biomedical engineering solutions reduce the consequences of uncontrolled blood pressure, including stroke, kidney failure, and cardiovascular disease, by promoting real-time risk assessment, early clinical intervention, and customized therapeutic decisions.

Rapid decision-making in emergency and critical care settings has been significantly enhanced in acute care medicine by the integration of biosensors, point-of-care diagnostic equipment, automated monitoring systems, and AI-based triage tools. These tools facilitate early detection of life-threatening illnesses like sepsis, respiratory failure, and cardiac arrest, improve monitoring of unstable patients, and shorten diagnostic delays. Acute care teams can improve survival outcomes and operational efficiency by acting sooner thanks to real-time data analysis and prompt clinical alarms.

This study highlights a number of issues that need to be resolved in order to optimize the benefits of biomedical engineering advancements, despite their obvious advantages. Access discrepancies are caused by the high expenses of advanced technologies, especially in healthcare systems with limited resources. Smooth incorporation into clinical workflows is still hampered by interoperability problems across hospital information systems and devices. Clinical deployment is frequently delayed by regulatory approval procedures, despite its importance for safety and effectiveness. Additionally, in order to successfully use new technology and understand complicated datasets, clinicians need sufficient training.

In the future, cooperation between engineers, physicians, legislators, and business stakeholders will be essential to the sustainability and scalability of biomedical engineering developments. Widespread adoption will require sustained investment in R&D together with user-centered device design and equitable access initiatives. Clinicians will be better able to incorporate these advances into their daily practice with the support of interdisciplinary education and training programs.

To sum up, biomedical engineering is propelling revolutionary advancements in acute care medicine, cardiology, cancer, and hypertension. These technologies are transforming healthcare delivery and enhancing patient outcomes by facilitating earlier identification, continuous monitoring, precision medicines, and data-driven clinical decisions. The trend of innovation indicates that biomedical engineering will continue to be a key component of upcoming medical advancements, despite ongoing hurdles. These breakthroughs have the potential to dramatically lower the burden of disease and improve global health standards with further development, integration, and equitable implementation.

References

- Restrepo Tique, M., Araque, O., & Sanchez-Echeverri, L. A. (2024). Technological Advances in the Diagnosis of Cardiovascular Disease: A Public Health Strategy. *International Journal of Environmental Research and Public Health*, 21(8), 1083. <https://doi.org/10.3390/ijerph21081083>
- Gerc, V.; Masic, I.; Salihefendic, N.; Zildzic, M. Cardiovascular Diseases (CVDs) in COVID-19 Pandemic Era. *Mater. Socio-Medica* 2020, 32, 158. Available online: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7428924/> (accessed on 26 June 2024).
- Rubiés-Prat, J. Factores de riesgo cardiovascular. *Med. - Programa de Form. Médica Contin. Acreditado* 2005, 9, 2506–2513.
- Padua, G.R.; Jacobo, W.; Piñera, D.; Gladys, M.; Padua, R. Enfermedades no transmisibles. Tendencias actuales. *Revista Cubana de Salud y Trabajo* 2012, 13, 50. Available online: <https://revsaludtrabajo.sld.cu/index.php/revsyt/article/view/609> (accessed on 26 June 2024).
- Turcu, A.M.; Ilie, A.C.; Ștefăniu, R.; Țăranu, S.M.; Sandu, I.A.; Alexa-Stratulat, T.; Pîslaru, A.I.; Alexa, I.D. The impact of heart rate variability monitoring on preventing severe cardiovascular events. *Diagnostics* 2023, 13, 2384.
- Blanco-Colio, L.M.; Méndez-Barbero, N.; Pello Lázaro, A.M.; Aceña, Á.; Tarín, N.; Cristóbal, C.; Martínez-Milla, J.; González-Lorenzo, Ó.; Martín-Ventura, J.L.; Huelmos, A.; et al. MCP-1 predicts recurrent cardiovascular events in patients with persistent inflammation. *J. Clin. Med.* 2021, 10, 1137.
- Freak-Poli, R.; Hu, J.; Phyo, A.Z.Z.; Barker, S.F. Social isolation and social support influence health service utilisation and survival after a cardiovascular disease event: A systematic review. *Int. J. Environ. Res. Public Health* 2023, 20, 4853.
- Zheng, Z.; Zhang, P.; Yuan, F.; Bo, Y. Scientometric analysis of the relationship between a built environment and cardiovascular disease. *Int. J. Environ. Res. Public Health* 2022, 19, 5625.
- Attaran, M. Blockchain technology in healthcare: Challenges and opportunities. *Int. J. Healthc. Manag.* 2022, 15, 70–83.
- Sandeep, B.; Liu, X.; Huang, X.; Wang, X.; Mao, L.; Xiao, Z. Feasibility of artificial intelligence its current status, clinical applications, and future direction in cardiovascular disease. *Curr. Probl. Cardiol.* 2024, 49, 102349.
- Sikkander, A. R. M., Meenab, M., Yadav, H., Wahi, N., & Lakshmi, V. V. Appraisal of the Impact of Applying Organometallic Compounds in Cancer Therapy.
- Mohamed, S. A. R., Yadav, H., Meena, M., Wahi, N., & Kumar, K. (2024). A Review of Diagnostic Nano Stents: Part (I).
- Sikkander, A. M., & Nachiar, R. Assess of Hydrazine Sulphate (N₂H₆SO₄) in Opposition for The Majority of Cancer Cells.
- Mohamed, S. A. R., Yadav, H., Meena, M., & Lakshmi, V. V. (2024). A Review of Advances in the Development of Bioresorbable Nano Stents: Part (II).
- Sikkander, A. R. M., Vedhi, C., & Manisankar, P. (2011). Electrochemical stripping studies of amlodipine using Mwcnt modified glassy carbon electrode. *Chem Mater Res*, 1, 1-7.
- Sivakumar, R., Gopalakrishnan, P., & Razak, M. S. A. (2021). Comparative analysis of anti-reflection coatings on solar PV cells through TiO₂ and SiO₂ nanoparticles. *Pigment & Resin Technology*, 51(2), 171-177.
- Sikkander, A. M. (2022). Intrathecal Chemotherapy for Blood Cancer Treatment. In *Acta Biology Forum* (pp. 14-17).
- Sikkander, A. M. Duct Cancer Evaluation In Situ–Review.
- Sikkander, M., Vedhi, C., & Manisankar, P. (2012). Cyclic voltammetric determination of 1, 4-Dihydro pyridine drugs using MWCNTs modified glassy carbon electrode. *Der Chem. Sin*, 3, 413-420.
- Sikkander, A. M., & Nasri, N. S. Review on Inorganic Nano crystals unique benchmark of Nanotechnology.
- Holme, S., Richardson, S. M., Bella, J., & Pinali, C. (2025). Hydrogels for Cardiac Tissue Regeneration: Current and Future Developments. *International Journal of Molecular Sciences*, 26(5), 2309. <https://doi.org/10.3390/ijms26052309>
- Sanchis-Gomar, F.; Perez-Quilis, C.; Leischik, R.; Lucia, A. Epidemiology of coronary heart disease and acute coronary syndrome. *Ann. Transl. Med.* 2016, 4, 256.
- Mensah, G.A.; Fuster, V.; Murray, C.J.L.; Roth, G.A. Global Burden of Cardiovascular Diseases and Risks, 1990–2022. *J. Am. Coll. Cardiol.* 2023, 82, 2350–2473.
- Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2021 (GBD 2021); Institute for Health Metrics and Evaluation (IHME): Seattle, WA, USA, 2024; Available online: <http://www.healthdata.org/research-analysis/library/global-burden-disease-2021-findings-gbd-2021-study> (accessed on 13 January 2025).

25. World Health Organization. UN Decade of Healthy Ageing: Plan of Action 2021–2030. Available online: <https://cdn.who.int/media/docs/default-source/decade-of-healthy-ageing/decade-proposal-final-apr2020-en.pdf> (accessed on 12 December 2023).
26. Mensah, G.A.; Fuster, V.; Roth, G.A. A Heart-Healthy and Stroke-Free World: Using Data to Inform Global Action. *J. Am. Coll. Cardiol.* 2023, 82, 2343–2349.
27. Institute of Medicine Committee on Social Security Cardiovascular Disability Criteria. *Cardiovascular Disability: Updating the Social Security Listings*; National Academies Press: Washington, DC, USA, 2010.
28. Mendis, S.; Thygesen, K.; Kuulasmaa, K.; Giampaoli, S.; Mähönen, M.; Ngu Blackett, K.; Lisheng, L. World Health Organization definition of myocardial infarction: 2008-09 revision. *Int. J. Epidemiol.* 2011, 40, 139–146.
29. Burke, A.P.; Virmani, R. Pathophysiology of Acute Myocardial Infarction. *Med. Clin. N. Am.* 2007, 91, 553–572.
30. Lüscher, T.F. Myocardial infarction: Mechanisms, diagnosis, and complications. *Eur. Heart J.* 2015, 36, 947–949.
31. La Via, L., Sangiorgio, G., Stefani, S., Marino, A., Nunnari, G., Cocuzza, S., La Mantia, I., Cacopardo, B., Stracquadanio, S., Spampinato, S., Lavalle, S., & Maniaci, A. (2024). The Global Burden of Sepsis and Septic Shock. *Epidemiologia*, 5(3), 456-478. <https://doi.org/10.3390/epidemiologia5030032>
32. Singer, M.; Deutschman, C.S.; Seymour, C.W.; Shankar-Hari, M.; Annane, D.; Bauer, M.; Bellomo, R.; Bernard, G.R.; Chiche, J.D.; Coopersmith, C.M.; et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 2016, 315, 801–810.
33. Hotchkiss, R.S.; Moldawer, L.L.; Opal, S.M.; Reinhart, K.; Turnbull, I.R.; Vincent, J.-L. Sepsis and septic shock. *Nat. Rev. Dis. Primer* 2016, 2, 16045.
34. Shankar-Hari, M.; Phillips, G.S.; Levy, M.L.; Seymour, C.W.; Liu, V.X.; Deutschman, C.S.; Angus, D.C.; Rubenfeld, G.D.; Singer, M.; Sepsis Definitions Task Force. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016, 315, 775–787.
35. Fleischmann, C.; Scherag, A.; Adhikari, N.K.; Hartog, C.S.; Tsaganos, T.; Schlattmann, P.; Angus, D.C.; Reinhart, K.; International Forum of Acute Care Trialists. Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. *Am. J. Respir. Crit. Care Med.* 2016, 193, 259–272.
36. Rudd, K.E.; Johnson, S.C.; Agesa, K.M.; Shackelford, K.A.; Tsoi, D.; Kievlan, D.R.; Colombara, D.V.; Ikuta, K.S.; Kissoon, N.; Finfer, S.; et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: Analysis for the Global Burden of Disease Study. *Lancet* 2020, 395, 200–211.
37. WHO Calls for Global Action on Sepsis—Cause of 1 in 5 Deaths Worldwide. Consultato: 11 Giugno 2024. Available online: <https://www.who.int/news/item/08-09-2020-who-calls-for-global-action-on-sepsis---cause-of-1-in-5-deaths-worldwide> (accessed on 1 June 2024).
38. Adhikari, N.K.J.; Fowler, R.A.; Bhagwanjee, S.; Rubenfeld, G.D. Critical care and the global burden of critical illness in adults. *Lancet* 2010, 376, 1339–1346.
39. Schultz, M.J.; Dunser, M.W.; Dondorp, A.M.; Adhikari, N.K.J.; Iyer, S.; Kwizera, A.; Lubell, Y.; Papali, A.; Pisani, L.; Riviello, B.D.; et al. Current challenges in the management of sepsis in ICUs in resource-poor settings and suggestions for the future. *Intensive Care Med.* 2017, 43, 612–624.
40. Martin, G.S.; Mannino, D.M.; Eaton, S.; Moss, M. The epidemiology of sepsis in the United States from 1979 through 2000. *N. Engl. J. Med.* 2003, 348, 1546–1554.
41. Sikkander, A. M., Vedhi, C., & Manisankar, P. (2016). Utilization of sodium montmorillonite clay for enhanced electrochemical sensing of amlodipine. *Indian Journal of Chemistry*, 55, 571-575.
42. Yadava, C. H., Revanuri, N., & Sikkander, A. R. M. Tungsten-Based Compounds: A New Frontier in Cancer Diagnosis and Therapy.
43. Hiremath, G., Mohamed, S. A. R., Upadhyay, R., Acharya, D., Singh, K. P., & Wahi, N. Safety and Efficacy of Drug-Eluting Stents Improved Dramatically with Application of Nanotechnology.
44. Abdul Razak Mohamed Sikkander., RUTHENIUM ORGANOMETALLIC COMPOUNDS IN CANCER TREATMENT, *Biomedical Engineering: Applications, Basis and Communications*, Vol. 37, No. 01, 2430003 (2025) <https://doi.org/10.4015/S1016237224300037>
45. Rodrigues, J. J., Sikkander, A. R. M., Tripathi, S. L., Kumar, K., Mishra, S. R., & Theivanathan, G. (2025). Healthcare applications of computational genomics.
46. Sikkander, A. M., & Yasmeen, K. Review on Nanotechnology persecute vital role of Curative Applications in Medicinal Field and its ailing Effects.
47. Rodrigues, J. J., Sikkander, A. R. M., Tripathi, S. L., Kumar, K., Mishra, S. R., & Theivanathan, G. (2025). Artificial intelligence’s applicability in cardiac imaging.
48. Sikkander, A. R. M., Tripathi, S. L., & Theivanathan, G. (2025). Extensive sequence analysis: revealing genomic knowledge throughout various domains. In *Computational Intelligence for Genomics Data* (pp. 17-30). Academic Press.
49. Yasmeen, K., & Sikkander, A. M. (2021). Progression of Nanotools in Neuroscience. *J. Sci. Technol*, 6, 9-16.
50. Huang, G., Chen, X., & Liao, C. (2025). AI-Driven Wearable Bioelectronics in Digital Healthcare. *Biosensors*, 15(7), 410. <https://doi.org/10.3390/bios15070410>
51. Zheng, Y.; Tang, N.; Omar, R.; Hu, Z.; Duong, T.; Wang, J.; Wu, W.; Haick, H. Smart Materials Enabled with Artificial Intelligence for Healthcare Wearables. *Adv. Funct. Mater.* 2021, 31, 2105482.
52. Dai, Y.; Wang, J.; Gao, S. Advanced Electronics and Artificial Intelligence: Must-Have Technologies Toward Human Body Digital Twins. *Adv. Intell. Syst.* 2022, 4, 2100263.
53. Wasilewski, T.; Kamysz, W.; Gebicki, J. AI-Assisted Detection of Biomarkers by Sensors and Biosensors for Early Diagnosis and Monitoring. *Biosensors* 2024, 14, 356.
54. Zhang, Y.; Chen, H.; Song, Y. Wearable healthcare monitoring and therapeutic bioelectronics. *Wearable Electron.* 2025, 2, 18–22.
55. Liao, C.; Xiong, Y.; Fu, Y.; Chen, X.; Occhipinti, L.G. Organic semiconductors based wearable bioelectronics. *Wearable Electron.* 2025, 2, 23–39.

56. Kim, S.; Baek, S.; Sluyter, R.; Konstantinov, K.; Kim, J.H.; Kim, S.; Kim, Y.H. Wearable and implantable bioelectronics as eco-friendly and patient-friendly integrated nanoarchitectonics for next-generation smart healthcare technology. *EcoMat* 2023, 5, e12356.
57. Chen, W.; Zheng, X.; Zhou, Y.; Du, W.; Liang, F.; Yu, H.D.; Li, L. Recent Progress in Semi-Implantable Bioelectronics for Precision Health Monitoring. *Adv. Funct. Mater.* 2025, 2424463. [Google Scholar] [CrossRef]
58. Wang, B.; Lv, A.; Wu, H.; Guo, B.; Lu, Y.; Chang, Z.; Wu, Y.; Li, X.; Yang, Q.; Nie, J.; et al. Antifreezing Ultrathin Bioionic Gel-Based Wearable System for Artificial Intelligence-Assisted Arrhythmia Diagnosis in Hypothermia. *ACS Nano* 2025, 19, 8176–8188.
59. Wang, Y.; Feng, X.; Chen, X. Autonomous Bioelectronic Devices Based on Silk Fibroin. *Adv. Mater.* 2025, 37, e2500073.
60. Rivnay, J.; Raman, R.; Robinson, J.T.; Schreiber, C.; Cohen-Karni, T.; Galloway, K.E.; Veiseh, O. Integrating bioelectronics with cell-based synthetic biology. *Nat. Rev. Bioeng.* 2025, 3, 317–332.
61. Sikkander, A. M., Vedhic, & Manisankar, P. Enhanced electrochemical sensing of Nimodipine with Sodium montmorillonite clay.
62. Mohamed Sikkander, A. R., Mishra, S. R., Shankaranarayanan, S. and Chagini, S. (2025). The iPSC Based Models for Hereditary Arrhythmias: From Genotype Phenotype Studies to Precision Therapy. *SPC Journal of Medical and Healthcare*, 1(3), 184-191. doi: 10.48309/sjmh.2025.537906.1074
63. Mohamed Sikkander, A. R., Chagini, S., Mishra, S. R. and Subramanian, S. (2025). Integration of 6G Networks and Deep Learning for Advanced Biomedical Engineering Applications: Real Time Analytics, Remote Surgery, and Intelligent Healthcare Systems. *SPC Journal of Medical and Healthcare*, 1(3), 167-175. doi: 10.48309/sjmh.2025.537895.1073
64. C. Hazarathiah Yadav, Narendra Revanuri, and Abdul Razak Mohamed Sikkander, ORGANOMETALLIC COMPOUND'S PHOTOTOXICITY AGAINST CANCER CELLS, *Biomedical Engineering: Applications, Basis and Communications Online* Ready No Access, <https://doi.org/10.4015/S1016237225500206>
65. A. Mohamed Sikkander, Rajeev Ranjan, Sangeeta R Mishra. Artificial Intelligence in Cerebellum Activation. *International Journal of Cheminformatics*. 2024; 01(01):14-26. Available from: <https://journals.stmjournals.com/ijci/article=2024/view=143947>
66. Abdul Razak Mohamed Sikkander, Rajeev Ranjan, Sangeeta R Mishra. Nanoelectronics, Nanoparticles and Nanotechnology in Treatment of Psychological Disorders. *International Journal of Environmental Chemistry*. 2024; ():- Available from: <https://journals.stmjournals.com/ijec/article=2024/view=143513>
67. A. Mohamed Sikkander, Rajeev Ranjan, A. Mohamed Sikkander. Organometallic Osmium Compounds in Cancer Therapy. *International Journal of Advance in Molecular Engineering*. 2024; 01(02):01-25. Available from: <https://journals.stmjournals.com/ijame/article=2024/view=144940>
68. Abdul Mohamed Sikkander, Catalytic Activity Advancements in Organometallic Chemistry, <https://engineeringjournals.stmjournals.in/index.php/JoCC/issue/view/1274>
69. Mohamed Sikkander, A. R., Yadav, H. and Meena, M. (2024). The Study Examined the Effectiveness of a Nickel (II) Complex Containing 5-Acetyl-N-(adamantan-2-yl) Thiophene-2-Carboxamide as a Derivative for the Drug Isoniazid in Relation to Bacterial, Cancer and Tuberculosis Activities. *Advanced Journal of Chemistry, Section A*, 7(5), 501-521. doi: 10.48309/ajca.2024.443156.1490
70. Jeetendra Kumar Gupta, Abdul Razak Mohamed Sikkander, Faizan ul Haque Nagrami, Krishan Kumar, Nitin Wahi, 2023.
71. Gu, Y., & Fernandez, J. (2024). Advancements in Biomedical and Bioengineering Technologies in Sports Monitoring and Healthcare. *Bioengineering*, 11(8), 816. <https://doi.org/10.3390/bioengineering11080816>
72. West, S.W.; Clubb, J.; Torres-Ronda, L.; Howells, D.; Leng, E.; Vescovi, J.D.; Carmody, S.; Posthumus, M.; Dalen-Lorensen, T.; Windt, J. More than a Metric: How Training Load is Used in Elite Sport for Athlete Management. *Int. J. Sports Med.* 2021, 42, 300–306.
73. Li, P.; Lee, G.H.; Kim, S.Y.; Kwon, S.Y.; Kim, H.R.; Park, S. From Diagnosis to Treatment: Recent Advances in Patient-Friendly Biosensors and Implantable Devices. *ACS Nano* 2021, 15, 1960–2004.
74. Galli, A.; Montree, R.J.H.; Que, S.; Peri, E.; Vullings, R. An Overview of the Sensors for Heart Rate Monitoring Used in Extramural Applications. *Sensors* 2022, 22, 4035.
75. Chen, S.; Qi, J.; Fan, S.; Qiao, Z.; Yeo, J.C.; Lim, C.T. Flexible Wearable Sensors for Cardiovascular Health Monitoring. *Adv. Healthc. Mater.* 2021, 10, e2100116.
76. Yamane, T.; Kimura, M.; Morita, M. Application of nine-axis accelerometer-based recognition of daily activities in clinical examination. *Phys. Act. Health* 2024, 8, 29–46.
77. Zhang, M.; Zhang, C.; Shi, Q.; Zeng, S.; Balezentis, T. Operationalizing the telemedicine platforms through the social network knowledge: An MCDM model based on the CIPFOHW operator. *Technol. Forecast. Soc. Chang.* 2022, 174, 121303.
78. Vaghasiya, J.V.; Mayorga-Martinez, C.C.; Pumera, M. Telemedicine platform for health assessment remotely by an integrated nanoarchitectonics FePS3/rGO and Ti3C2-based wearable device. *npj Flex. Electron.* 2022, 6, 73.
79. Sumner, J.; Lim, H.W.; Chong, L.S.; Bundele, A.; Mukhopadhyay, A.; Kayambu, G. Artificial intelligence in physical rehabilitation: A systematic review. *Artif. Intell. Med.* 2023, 146, 102693.
80. Khoshmanesh, F.; Thurgood, P.; Pirogova, E.; Nahavandi, S.; Baratchi, S. Wearable sensors: At the frontier of personalised health monitoring, smart prosthetics and assistive technologies. *Biosens. Bioelectron.* 2021, 176, 112946.
81. Appraisal, recent advancement, and impacts of nanomedicine in cardiac asthma. *Journal of medical pharmaceutical and allied sciences*, V 12 - I 5, Pages - 6132 – 6138. Doi: <https://doi.org/10.55522/jmpas.V12I5.5214>

82. A Mohamed Sikkander, Nanosilicones in Sub Glandular and Sub Muscular Implant Breast Transplantation <https://chemical.journalspub.info/index.php?journal=JAAC&page=index>
83. A. Mohamed Sikkander, Assess of Basal cell carcinoma, Vol 8, No 2 (2022) <https://chemical.journalspub.info/index.php?journal=JCME&page=issue&op=view&path%5B%5D=273>
84. Ho D, Quake SR, McCabe ERB, Chng WJ, Chow EK, Ding X, Gelb BD, Ginsburg GS, Hassenstab J, Ho CM, Mobley WC, Nolan GP, Rosen ST, Tan P, Yen Y, Zarrinpar A. Enabling Technologies for Personalized and Precision Medicine. *Trends Biotechnol.* 2020 May;38(5):497-518. doi: 10.1016/j.tibtech.2019.12.021
85. Abhinav, V., Basu, P., Verma, S. S., Verma, J., Das, A., Kumari, S., Yadav, P. R., & Kumar, V. (2025). Advancements in Wearable and Implantable BioMEMS Devices: Transforming Healthcare Through Technology. *Micromachines*, 16(5), 522. <https://doi.org/10.3390/mi16050522>
86. Ho, D.; Quake, S.R.; McCabe, E.R.B.; Chng, W.J.; Chow, E.K.; Ding, X.; Gelb, B.D.; Ginsburg, G.S.; Hassenstab, J.; Ho, C.-M.; et al. Enabling Technologies for Personalized and Precision Medicine. *Trends Biotechnol.* 2020, 38, 497–518.
87. Assalve, G.; Lunetti, P.; Di Cagno, A.; De Luca, E.W.; Aldegheri, S.; Zara, V.; Ferramosca, A. Advanced wearable devices for monitoring sweat biochemical markers in athletic performance: A comprehensive review. *Biosensors* 2024, 14, 574.
88. Kassanos, P.; Hourdakakis, E. Implantable Passive Sensors for Biomedical Applications. *Sensors* 2025, 25, 133.
89. Erdem, A.; Eksin, E.; Senturk, H.; Yildiz, E.; Maral, M. Recent developments in wearable biosensors for healthcare and biomedical applications. *TrAC Trends Anal. Chem.* 2024, 171, 117510.
90. Vo, D.-K.; Trinh, K.T.L. Advances in Wearable Biosensors for Healthcare: Current Trends, Applications, and Future Perspectives. *Biosensors* 2024, 14, 560.
91. Sanjay; Kumar, V.; Vohra, A. Sensitivity enhancement using triple metal gate work function engineering of junctionless cylindrical gate all around SiNW MOSFET based biosensor for neutral biomolecule species detection for upcoming sub 14 nm technology node. *Mater. Sci. Eng. B* 2024, 306, 117459.
92. Kong, L.; Li, W.; Zhang, T.; Ma, H.; Cao, Y.; Wang, K.; Zhou, Y.; Shamim, A.; Zheng, L.; Wang, X.; et al. Wireless Technologies in Flexible and Wearable Sensing: From Materials Design, System Integration to Applications. *Adv. Mater.* 2024, 36, 2400333.
93. Yogev, D.; Goldberg, T.; Arami, A.; Tejman-Yarden, S.; Winkler, T.E.; Maoz, B.M. Current state of the art and future directions for implantable sensors in medical technology: Clinical needs and engineering challenges. *APL Bioeng.* 2023, 7, 031506.
94. Huanbutta, K.; Puri, V.; Sharma, A.; Singh, I.; Sriamornsak, P.; Sangnim, T. Rise of implantable drugs: A chronicle of breakthroughs in drug delivery systems. *Saudi Pharm. J.* 2024, 32, 102193.
95. Mariello, M.; Proctor, C.M. Wireless Power and Data Transfer Technologies for Flexible Bionic and Bioelectronic Interfaces: Materials and Applications. *Adv. Mater. Technol.* 2025, 10, 2400797.
96. Shuvo, M.M.H.; Titirsha, T.; Amin, N.; Islam, S.K. Energy harvesting in implantable and wearable medical devices for enduring precision healthcare. *Energies* 2022, 15, 7495.
97. Liu, Y.; Yu, Q.; Yang, L.; Cui, Y. Materials and biomedical applications of implantable electronic devices. *Adv. Mater. Technol.* 2023, 8, 2200853.
98. Jafleh, E.A.; Alnaqbi, F.A.; Almaeeni, H.A.; Faqeeh, S.; Alzaabi, M.A.; Al Zaman, K.; Alnaqbi, F.; Almaeeni, H.; Alzaabi, M. The role of wearable devices in chronic disease monitoring and patient care: A comprehensive review. *Cureus* 2024, 16, e68921.
99. Sridhar, A.R.; Cheung, J.W.; Lampert, R.; Silva, J.N.A.; Gopinathannair, R.; Sotomonte, J.C.; Tarakji, K.; Fellman, M.; Chrispin, J.; Varma, N.; et al. State of the art of mobile health technologies use in clinical arrhythmia care. *Commun. Med.* 2024, 4, 218.
100. Odeh, V.A.; Chen, Y.; Wang, W.; Ding, X. Recent Advances in the Wearable Devices for Monitoring and Management of Heart Failure. *Rev. Cardiovasc. Med.* 2024, 25, 386.
101. Yin, Z.; Yang, Y.; Hu, C.; Li, J.; Qin, B.; Yang, X. Wearable respiratory sensors for health monitoring. *NPG Asia Mater.* 2024, 16, 8.
102. Wu, K.Y.; Mina, M.; Carbonneau, M.; Marchand, M.; Tran, S.D. Advancements in Wearable and Implantable Intraocular Pressure Biosensors for Ophthalmology: A Comprehensive Review. *Micromachines* 2023, 14, 1915.
103. Pons-Faudoa, F.P.; Ballerini, A.; Sakamoto, J.; Grattoni, A. Advanced implantable drug delivery technologies: Transforming the clinical landscape of therapeutics for chronic diseases. *Biomed. Microdevices* 2019, 21, 47.
104. Perez, F.P.; Walker, B.; Morisaki, J.; Kanakri, H.; Rizkalla, M. Neurostimulation devices to treat Alzheimer's disease. *Explor. Neurosci.* 2025, 4, 100674.
105. A. Mohamed Sikkander*, Nanoemulsion in Ophthalmology, Vol 8, No 2 (2022) <https://chemical.journalspub.info/index.php?journal=JAWC M&page=index>
106. A. Mohamed Sikkander*, Advancement of Agricultural Biotechnology in USA Vol 9, No 2 (2023) <https://chemical.journalspub.info/index.php?journal=IJCPD&page=index>
107. Sikkander, A. M., Hemavathy, N., & Mishra, S. R. (2022). Tactile System for Visually Impaired People Using Embedded Technology.
108. RamaNachiar, R., & Yasmeen, K. (2022). Assess of Calcitonin against Arthritis.
109. RamaNachiar, R., & Yasmeen, K. (2022). Artificial Neural Networks (ANNs) in Lungs Cancer Detection.
110. RamaNachiar, R., & Yasmeen, K. (2022). Spiking Neural Network (SNN) Using to Detect Breast Cancer.
111. Wang, B., Hu, S., Teng, Y. et al. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. *Sig Transduct Target Ther* 9, 200 (2024). <https://doi.org/10.1038/s41392-024-01889-y>
112. Sikkander, A. M. (2022). Duct Cancer.
113. Sikkander, A. M., Mishra, S. R., & Kavitha, K. (2022). Review on Nanogold and Nano silver for cervical Cancer Therapy. *Journal of Science Letters*, 1, 04.

114. Dr. A. Mohamed Sikkander, Ms. S. Sasikala, Dr. K. Kavitha, and Mr. T. Niruban Balu, "Efficacy of Nanomaterials and Nanotechnology in Diagnosis and Treatment of Heart Diseases", *International Journal of Innovative Research in Science and Technology*, Vol. 01, Issue 04, November 2021, pp.:017-021
115. Sikkander, A. M., & Yasmeen, K. (2021). Review on Green Synthesis of Positively Charged Biocompatible Gold Nanoparticles in Water: Use of Ascorbic Acid as Reducing Agent. *Technology*, 6(02).
116. Ramachandran, K., & Sikkander, A. M. (2021). Biomedical Signal Processing: Understanding Its Importance and Several Fundamental Steps. *TRANSACTION ON BIOMEDICAL ENGINEERING APPLICATIONS AND HEALTHCARE*. Учредители: Technoarete Research and Development Association, 2(2).
117. Sikkander, A. M., & Yasmeen, K. (2021). Global Anesthesia & pain Medicine.
118. Sikkander, A. M. (2020). Favipiravir is a Broad Spectrum Antiviral Prescription Famous to Selectivity Block RNA-Dependent RNA Polymerase (RdRp) and SARS-COVID-19
119. A. Mohamed Sikkander ,SK.Rafi, K.Kavitha3Exigency for Use of Nano Material Biosensors In Diagnosis of Disease *Journal of Science and Technology* ISSN: 2456-5660 Volume 5, Issue 2, March-April 2020, PP 25-31 www.jst.org.in
120. Mohamed Sikkander,A. . R. , Meena,M. , Yadav,H. , Wahi,N. and Lakshmi,V. V. (2024). Appraisal of the Impact of Applying Organometallic Compounds in Cancer Therapy. *Journal of Applied Organometallic Chemistry*, 4(2), 145-166. doi: 10.48309/jaoc.2024.433120.1154
121. Sikkander, A. M., & Abbas, H. S. A novel biosensor for pathogens diagnosis. *J Clin Bioanal Chem*. 2021; 5 (4): 1, 4.
122. Dwivedi, V., & Sikkander, A. M. The Potential Risks of Genetically Altered Animals on the Environment.
123. Sikkander, A. M., Bassyouni, F., Yasmeen, K., Mishra, S. R., & Lakshmi, V. V. (2023). Synthesis of Zinc Oxide and Lead Nitrate Nanoparticles and their Applications: Comparative Studies of Bacterial and Fungal (*E. coli*, *A. Niger*).
124. Sikkander, A. R. M., Vedhi, C., & Manisankar, P. (2012). Electrochemical determination of calcium channel blocker drugs using multiwall carbon nanotube-modified glassy carbon electrode.